1.61
-0.20 (-11.05%)
Penutupan Terdahulu | 1.81 |
Buka | 1.73 |
Jumlah Dagangan | 477,727 |
Purata Dagangan (3B) | 576,891 |
Modal Pasaran | 56,464,632 |
Harga / Jualan (P/S) | 650.84 |
Harga / Buku (P/B) | 1.48 |
Julat 52 Minggu | |
Tarikh Pendapatan | 24 Apr 2025 - 28 Apr 2025 |
Margin Operasi (TTM) | -55,504.94% |
EPS Cair (TTM) | -1.39 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 4.48% |
Nisbah Semasa (MRQ) | 10.25 |
Aliran Tunai Operasi (OCF TTM) | -34.81 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.49 M |
Pulangan Atas Aset (ROA TTM) | -32.85% |
Pulangan Atas Ekuiti (ROE TTM) | -100.05% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Actinium Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 0.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 0.00 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 1.79% |
% Dimiliki oleh Institusi | 29.67% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Los Angeles Capital Management Llc | 31 Dec 2024 | 213,950 |
Squarepoint Ops Llc | 31 Dec 2024 | 183,262 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |